Group 1 - The company, David Medical, announced on September 2 that it has received a "Notice of Acceptance" from the Zhejiang Provincial Drug Administration for its electric surgical table product [1] - The electric surgical table is designed to support high weight capacity in any position, catering to the variability of surgeries and different patient positions [1] - The modular design of the table surface allows it to be suitable for a wide range of surgical procedures [1]

Core Viewpoint - David Medical (300314.SZ) has recently obtained a "Acceptance Notice" issued by the Zhejiang Provincial Drug Administration for its product, an electric surgical table [1] Group 1 - The company has received regulatory approval for its electric surgical table [1]

戴维医疗公告称，公司于近日取得1项由浙江省药品监督管理局颁发的《受理通知书》，受理号为：械 受20254028265。本次申报产品为电动手术台，采用电动液压控制方式，通过微型按键开关控制器灵活 控制台面的各种运动，以满足手术所需的各种体位要求。上述医疗器械产品目前所处的审批阶段为注册 申请受理，后续所需的审批流程为技术审评、行政审批、制证。上述品种注册申请受理对公司近期业绩 不会产生影响，后续各阶段所需的时间和结果均具有一定的不确定性。 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-045 宁波戴维医疗器械股份有限公司 关于公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得1 项由浙江省药品监督管理局颁发的《受理通知书》，受理号为：械受 20254028265。具体情况如下： | 序号 | 产品名称 | 注册分类 | 临床用途 | | --- | --- | --- | --- | | | | | 本设备用于常规手术、神经外科、胸腹外 科、骨科、泌尿外科肛肠科、整形外科、 | | 1 | 电动手术台 | Ⅱ类 | 妇科，肝胆外科及普外科手术等医疗过程 | | | | | 的患者多体位支撑与操作，使其躺卧成不 | | | | | 同的姿势。 | 电动手术台是手术治疗中不可缺少的基础医疗设备，主要用于支撑患 者身体、调整手术体位、充分暴露手术野，使医护人员在方便、舒适的条 件下顺利完成各类手术。其核心价值是在于是否安全舒适、好用且耐用。 本次申报产品为电动手术台，采用电动液压控制方式，通过 ...

今年上半年，戴维医疗坚持实施创新驱动发展战略，持续加大研发投入，优化研发体系，加速产品迭代 升级。公司研发投入达2552.45万元，占营业收入的10.16%。截至六月末，公司及子公司累计拥有专利 257项，其中发明专利70项、实用新型专利138项、外观设计专利49项，计算机软件著作权9项。 （编辑 张伟） 本报讯 （记者吴奕萱）8月22日，宁波戴维医疗器械股份有限公司（以下简称"戴维医疗"）发布2025年 半年度报告，公司实现营业收入2.51亿元，较上年同期下降5.48%；实现归属于上市公司股东的净利润 5097.67万元，较上年同期增长9.57%。 公告显示，戴维医疗通过持续深化研发创新、积极拓展市场空间、深入推进精细化管理等关键举措，实 现了经营业绩的稳健发展。 ...

Core Viewpoint - David Medical (300314) reported a mixed performance in its 2025 interim report, with a decline in total revenue but an increase in net profit, indicating improved profitability despite challenges in sales [1]. Financial Performance - Total revenue for the first half of 2025 was 251 million yuan, a decrease of 5.48% year-on-year [1]. - Net profit attributable to shareholders reached 50.98 million yuan, an increase of 9.57% year-on-year [1]. - In Q2 2025, total revenue was 130 million yuan, up 17.74% year-on-year, while net profit was 28.41 million yuan, a significant increase of 237.44% year-on-year [1]. - Gross margin improved to 58.4%, up 0.32% year-on-year, and net margin increased to 20.29%, up 15.92% year-on-year [1]. - Total expenses (selling, administrative, and financial) amounted to 73.16 million yuan, accounting for 29.12% of revenue, an increase of 1.58% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) rose to 0.18 yuan, a 9.6% increase year-on-year [1]. - Net asset value per share increased to 4.16 yuan, up 3.41% year-on-year [1]. - Operating cash flow per share was -0.01 yuan, a significant decrease of 607.75% year-on-year, attributed to reduced cash received from sales [1]. Cash Flow Analysis - Net cash flow from operating activities decreased by 607.75%, primarily due to a reduction in cash received from sales [1]. - Net cash flow from investing activities increased by 116.06%, driven by a rise in recovered structured deposits compared to the previous year [2]. - Net cash flow from financing activities rose by 51.39%, as cash paid for dividend distribution decreased compared to the previous year [2]. Business Evaluation - The company's return on invested capital (ROIC) was 3.99%, indicating weak capital returns [3]. - The net profit margin for the previous year was 10.87%, suggesting average value addition from products or services [3]. - Historical data shows a median ROIC of 7.56% over the past decade, with the lowest ROIC recorded in 2018 at 3.51%, reflecting generally weak investment returns [3].

Core Viewpoint - David Medical's stock price increased by 5.38% to 15.47 yuan, reflecting positive market sentiment despite a decline in revenue [1] Financial Performance - In the first half of 2025, David Medical reported a revenue of 251 million yuan, a year-on-year decrease of 5.48% [1] - The net profit attributable to shareholders was 50.98 million yuan, showing a year-on-year increase of 9.57% [1] Stock Market Activity - The opening price was 15.76 yuan, with a high of 16.95 yuan and a low of 15.22 yuan, indicating volatility during the trading session [1] - The trading volume reached 352,300 hands, with a total transaction value of 562 million yuan [1] - On the same day, there was a net inflow of 15.86 million yuan from main funds, accounting for 0.71% of the circulating market value [1] - Over the past five days, the net inflow from main funds totaled 9.63 million yuan, representing 0.43% of the circulating market value [1] Company Overview - David Medical operates in the medical device sector, focusing on the research, production, and sales of obstetric and pediatric care equipment, as well as minimally invasive surgical instruments [1] - The company is also expanding its product offerings to include emergency surgical ICU products [1] Corporate Governance - The fifth supervisory board's thirteenth meeting approved multiple proposals, indicating ongoing corporate governance activities [1]

Core Viewpoint - David Medical's stock closed at 15.47 yuan, up 5.38%, with a rolling PE ratio of 72.19 times, indicating a higher valuation compared to the industry average [1] Company Overview - David Medical specializes in the research, production, and sales of obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1] - The company holds a total of 257 patents, including 70 invention patents, 138 utility model patents, 49 design patents, and 9 software copyrights [1] Financial Performance - For the first half of 2025, David Medical reported revenue of 251 million yuan, a year-on-year decrease of 5.48%, while net profit was 50.98 million yuan, an increase of 9.57%, with a gross profit margin of 58.40% [1] Market Position - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, positioning David Medical at the 95th rank within the industry [1][2] - As of August 20, 2025, the number of shareholders in David Medical increased to 22,900, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

2025年8月22日，戴维医疗(300314.SZ)发布2025年中报。 公司营业总收入为2.51亿元。归母净利润为5097.67万元，较去年同报告期归母净利润增加445.05万元， 同比较去年同期上涨9.57%。经营活动现金净流入为-398.39万元。 公司最新毛利率为58.40%，较上季度毛利率增加1.27个百分点，实现2个季度连续上涨，较去年同期毛 利率增加0.19个百分点。最新ROE为4.26%，较去年同期ROE增加0.24个百分点。 公司摊薄每股收益为0.18元，较去年同报告期摊薄每股收益增加0.02元，同比较去年同期上涨9.60%。 公司最新总资产周转率为0.18次。最新存货周转率为0.55次。 公司股东户数为1.94万户，前十大股东持股数量为1.97亿股，占总股本比例为68.44%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 陈再宏 | 45.81% | | 2 | 陈再慰 | 20.25% | | 3 | BARCLAYS BANK PLC | 0.42% | | 4 | 李则东 | 0.34% | | 5 | 中国 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，戴维医疗发布公告称，2025年半年度公司实现营业收入251，256，793.39 元，同比下降5.48%；归属于上市公司股东的净利润为50，976，694.29元，同比增长9.57%。 ...